News
Jacob Sands, MD, discusses the data that support the FDA accelerated approval of Dato-DXd in EGFR-positive non–small cell ...
As July concludes, the landscape of hematologic oncology continues to evolve, with notable progress in multiple myeloma, ...
HealthDay News — In a study published online July 9 in Blood Cancer Discovery, real-world outcomes are described for teclistamab, a T-cell-engaging bispecific antibody that targets multiple myeloma ...
Early data from the DURIPANC study shows promising safety and survival benefits of rintatolimod and durvalumab for metastatic ...
Clinical Trials Arena on MSN9h
Eli Lilly eyes SoC status as Jaypirca proves superior to Imbruvica in CLL/SLLEli Lilly’s Jaypirca (pirtobrutinib) has been shown to be superior to Johnson & Johnson (J&J) and AbbVie’s star Bruton's ...
Corticosteroid use, particularly at high doses, decreases the effectiveness of ICI therapy in patients with non–small cell ...
Actuate Therapeutics' elraglusib shows promise in metastatic pancreatic cancer. Upcoming FDA meeting may accelerate approval.
Stocktwits on MSN1d
Eli Lilly’s Cancer Drug Demonstrates Better Effectiveness Than AbbVie’s In Late Stage Trial: Retail Believes In Holding The StockEli Lilly and Company (LLY) on Tuesday said that its cancer drug Jaypirca was more effective than AbbVie’s drug Imbruvica in ...
AbbVie is seeking a new way to fight chronic lymphocytic leukemia by combining its oncology drug Venclexta with another ...
Supervive 1.0 is here, and while some of its big changes have been met with plaudits, its new progression system has left ...
In a randomized pilot study recently published in the Journal for ImmunoTherapy of Cancer, an international research team led ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback